Privia Health: Overlooked or Overrated | Business and Finance News

Privia Health’s stock lags with a modest 3.6% gain in 2026, hindered by limited distribution, weak cash flow margins, and zero ROIC—making it a tough play in a crowded, regulated space. With a pricey P/E of 23.6, investors are looking elsewhere, especially toward high-growth software stocks that deliver stronger returns and smarter capital use. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/ec5dacca6c6c9777